KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBT Margin (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EBT Margin data on record, last reported at 26.87% in Q4 2025.

  • For Q4 2025, EBT Margin rose 915163.0% year-over-year to 26.87%; the TTM value through Dec 2025 reached 36.47%, down 3341.0%, while the annual FY2025 figure was 36.47%, 281.0% up from the prior year.
  • EBT Margin reached 26.87% in Q4 2025 per REGN's latest filing, down from 46.97% in the prior quarter.
  • Across five years, EBT Margin topped out at 52122.22% in Q2 2021 and bottomed at 11000.68% in Q2 2024.
  • Average EBT Margin over 5 years is 1245.54%, with a median of 28.51% recorded in 2025.
  • Peak YoY movement for EBT Margin: surged 5207515bps in 2021, then crashed -5019582bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 21.38% in 2021, then crashed by -9282bps to 1963.6% in 2022, then plummeted by -219bps to 6271.04% in 2023, then tumbled by -46bps to 9124.76% in 2024, then soared by 100bps to 26.87% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 26.87% in Q4 2025, 46.97% in Q3 2025, and 41.32% in Q2 2025.